Fish Oil and Heart Health: What the REDUCE-IT Trial Really Proved

In November 2018, the results of the REDUCE-IT trial were published in the New England Journal of Medicine — and the omega-3 world has not been the same since. The trial showed that high-dose EPA supplementation reduced major cardiovascular events by 25% in high-risk patients, cutting cardiovascular death by 20%. It was one of the most significant cardiovascular trial results in years.

But the trial also sparked significant controversy, a deeper question about how fish oil actually works on the heart, and — crucially for consumers — serious questions about whether standard over-the-counter fish oil provides the same benefits. Here is what you need to know.

What REDUCE-IT Actually Tested

REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid–Intervention Trial) enrolled 8,179 adults who were already on statin therapy but still had elevated triglycerides (between 1.5 and 5.6 mmol/L). Participants were randomised to either 4 grams daily of icosapentaenoic acid ethyl ester (a purified, pharmaceutical-grade EPA — sold as Vascepa in the US) or a placebo.

Over a median follow-up of 4.9 years, the EPA group showed:

• 25% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death, unstable angina requiring hospitalisation, coronary revascularisation)
• 20% reduction in cardiovascular death
• 31% reduction in heart attack
• 28% reduction in stroke
• Triglycerides reduced by approximately 19%

The number needed to treat (NNT) to prevent one major cardiovascular event over 5 years was 21 — meaning for every 21 high-risk patients taking high-dose EPA, one major cardiovascular event was prevented. For a drug intervention, this is a very strong result.

The Mineral Oil Controversy

The REDUCE-IT results were not universally celebrated. The trial's placebo was mineral oil — a substance that is metabolically inert in most contexts, but which, it turned out, raises LDL cholesterol, CRP (an inflammation marker), and other cardiovascular risk markers when consumed daily over years. Critics argued that the placebo made the EPA group look better than it should have, because the placebo group was actively worsened by the mineral oil.

This is not a trivial criticism. A 2020 analysis in the European Heart Journal estimated that up to one-third of REDUCE-IT's apparent cardiovascular benefit could be attributable to the harmful effects of the mineral oil placebo rather than the benefits of EPA alone.

The trial's defenders counter that even after adjusting for this potential confounder, a meaningful cardiovascular benefit remains — and that several biomarkers (including inflammation markers and plaque characteristics) showed clear improvements in the EPA group independent of the placebo comparison.

The honest conclusion: REDUCE-IT demonstrated a real, meaningful cardiovascular benefit from high-dose purified EPA. The magnitude of that benefit may be somewhat overstated due to the placebo choice, but the direction of the effect is not in doubt.

Why Does High-Dose EPA Reduce Cardiovascular Events?

Triglyceride reduction alone does not explain the magnitude of benefit seen in REDUCE-IT. EPA's cardiovascular effects are now understood to work through multiple simultaneous mechanisms:

1. Membrane Stabilisation

EPA incorporates into atherosclerotic plaque and cardiac cell membranes, making plaques more stable and less prone to rupture. A sub-study of REDUCE-IT using intravascular ultrasound imaging found that the EPA group showed significantly less plaque progression and more plaque stabilisation over the trial period.

2. Anti-Inflammatory Effects

EPA suppresses the production of pro-inflammatory eicosanoids derived from arachidonic acid and promotes the formation of resolvins — molecules that actively resolve inflammation in arterial walls. Atherosclerosis is fundamentally an inflammatory disease, and EPA's anti-inflammatory activity directly targets its root mechanism.

3. Anti-Thrombotic Effects

EPA reduces platelet aggregation and thromboxane A2 production, lowering the risk of blood clots forming on ruptured plaques — the immediate mechanism of most heart attacks.

4. Triglyceride Reduction

At 4g daily, EPA reduces triglycerides by 20–30% through reduced hepatic triglyceride synthesis and increased triglyceride clearance. Very high triglycerides (above 5.6 mmol/L) are an independent cardiovascular risk factor.

5. Membrane Fluidity

EPA increases the fluidity of cardiac cell membranes, which reduces arrhythmia risk. A separate analysis found that the REDUCE-IT EPA group had significantly fewer sudden cardiac death events.

What About Standard Fish Oil Supplements?

This is the critical question for consumers, and the answer is more nuanced than supplement marketing typically suggests.

REDUCE-IT used 4g of pure EPA — not a standard mixed EPA+DHA fish oil supplement. A typical 1,000mg fish oil capsule contains approximately 180mg EPA and 120mg DHA. To reach the REDUCE-IT dose of 4g EPA, you would need to take roughly 22 standard capsules daily — clearly impractical.

Several earlier trials using standard mixed EPA+DHA fish oil at more moderate doses (1–3g daily) showed neutral or modest cardiovascular results, including the large ORIGIN trial (1g combined EPA+DHA, neutral result) and ASCEND trial (1g combined, modest but significant benefit).

A 2021 meta-analysis in JAMA Cardiology pooled data from 13 large omega-3 cardiovascular trials and found that:

• High-dose EPA-only supplementation (≥2g EPA daily): significant 18% reduction in cardiovascular events
• Mixed EPA+DHA at any dose: smaller, less consistent effects
• Low-dose mixed omega-3 (<1g daily): no significant cardiovascular benefit

The evidence therefore supports a dose-dependent, EPA-dominant effect on cardiovascular outcomes. Standard fish oil at standard doses does provide benefits — including modest triglyceride reduction, anti-platelet effects, and anti-inflammatory activity — but the dramatic event-reduction seen in REDUCE-IT requires pharmaceutical-grade high-dose EPA.

What This Means for You

The REDUCE-IT results are highly relevant to a specific population: people with elevated triglycerides who are already on statins and have established cardiovascular disease or high cardiovascular risk. For this group, prescription high-dose EPA (Vascepa/icosapentaenoic acid) is now a guideline-supported treatment in the US, endorsed by the American Heart Association and American College of Cardiology.

For the broader population taking fish oil for general cardiovascular health and anti-ageing:

• A combined EPA+DHA dose of at least 1–2g daily provides meaningful anti-inflammatory, anti-platelet, and modest triglyceride-lowering benefits
• EPA-dominant formulations (EPA≥60%) may provide greater cardiovascular benefit than DHA-dominant ones for heart health specifically
• Taking fish oil with a fat-containing meal significantly improves absorption
• The Omega-3 Index (the percentage of EPA+DHA in red blood cell membranes) is emerging as a clinically useful biomarker of omega-3 status — a value above 8% is associated with significantly lower cardiovascular risk. Most adults in Western countries are at 4–5%.

The Bottom Line

REDUCE-IT proved beyond reasonable doubt that high-dose pharmaceutical EPA dramatically reduces cardiovascular events in high-risk patients. The trial's mineral oil placebo introduced some uncertainty about the precise magnitude of benefit, but not about the direction. For the general public, these results validate EPA's cardiovascular importance and support the use of EPA-rich fish oil at meaningful doses — while making clear that the dramatic REDUCE-IT benefits require pharmaceutical dosing that goes well beyond standard supplement use.